The U.S. viral vectors and plasmid DNA manufacturing market reached USD 2.55 billion in 2025 and is projected to hit USD 9.62 billion by 2035, growing at a CAGR of 14.20%, driven by rising demand for gene therapy, cell therapy, and advanced biologics.

U.S. Viral Vectors and Plasmid DNA Manufacturing Market Statical Scope

In the U.S., the viral vector and plasmid DNA manufacturing market has expanded primarily due to adherence to good manufacturing practices, which enhance productivity and quality while providing flexibility and expertise coupled with advanced equipment. The growing prevalence of targeted diseases and increasing government investments contribute significantly to market growth. The landscape of cell and gene therapy manufacturing remains highly competitive, influenced by numerous contract manufacturers and research organizations. Additionally, the entrance of new players and the expansion of facilities by existing entities have intensified competition within the U.S. market. Major players, such as Thermo Fisher Scientific, Inc. and Lonza, have implemented various strategies to fortify their market presence.

U.S. Viral Vectors and Plasmid DNA Manufacturing Market Share, By Vector Type, 2025 (%)

• Adeno-associated virus (AAV)- Adeno-associated virus (AAV) leads the market, with a share of 30%, driven by gene therapy programs, efficient gene delivery performance, and favorable safety characteristics.
• Lentivirus- Lentivirus holds a significant share of 20%, supported by rising use in cell therapy development and stable gene transfer applications.
• Adenovirus- Adenovirus represents a notable segment, with a share of 16%, driven by continued demand in vaccine development and targeted therapeutic applications.
• Plasmids- Plasmids account for a share of 14%, supported by growing use in DNA-based therapeutics and vector production support.

U.S. Viral Vectors and Plasmid DNA Manufacturing Market Share, By Workflow, 2025 (%)

• Upstream manufacturing- Upstream manufacturing dominates the market, with a share of 60%, driven by rising vector production demand and expansion of cell culture activities.
• Downstream manufacturing- Downstream manufacturing holds a share of 40%, supported by growing requirements for purification, processing, and quality assurance.

U.S. Viral Vectors and Plasmid DNA Manufacturing Market Share, By Application, 2025 (%)

• Gene therapy- Gene therapy leads the market, with a share of 45%, driven by strong clinical development activity and growing commercialization of gene-based treatments.
• Cell therapy- Cell therapy holds a significant share of 25%, supported by rising investment in advanced therapies and expanding development pipelines.
• Vaccinology- Vaccinology accounts for a share of 10%, supported by continued demand for vector-based vaccine development and production.
• Antisense & RNAi therapy- Antisense & RNAi therapy represents a segment, with a share of 12%, driven by increasing focus on next-generation nucleic acid therapeutics.

U.S. Viral Vectors and Plasmid DNA Manufacturing Market Share, By End-use, 2025 (%)

• Pharmaceutical and biopharmaceutical companies- Pharmaceutical and biopharmaceutical companies dominate the market, with a share of 75%, driven by strong outsourcing demand, and expanding therapy pipelines.
• Research institutes- Research institutes hold a significant share of 25%, supported by ongoing research activity and the development of new vector technologies.

U.S. Viral Vectors and Plasmid DNA Manufacturing Market Share, By Disease, 2025 (%)

• Cancer- Cancer leads the market, with a share of 50%, driven by a growing focus on oncology-related gene and cell therapy development.
• Genetic disorders- Genetic disorders hold a share of 20%, supported by increasing therapeutic development targeting inherited and rare diseases.
• Infectious diseases- Infectious diseases account for a share of 16%, driven by continued investment in vaccine and antiviral therapeutic development.

Top Companies in the U.S. Viral Vectors and Plasmid DNA Manufacturing Market

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent Inc.
• Wuxi Biologics
• Takara Bio Inc.
• Waisman Biomanufacturing
• Genezen laboratories
• Batavia Biosciences
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• Audentes Therapeutics
• BioMarin Pharmaceutical
• RegenxBio, Inc.

Segments Covered in the Report

By Vector Type

• Adeno-associated virus (AAV)
• Lentivirus
• Adenovirus
• Retrovirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others